13726-21-1

Basic information

• Product Name: (4-CHLORO-3-METHOXYPHENYL)ACETONITRILE
• Synonyms: (4-CHLORO-3-METHOXYPHENYL)ACETONITRILE;RARECHEM AL MP 0203;2-(4-Chloro-3-Methoxyphenyl)acetonitrile;2-(4-Chloro-3-methoxyphenyl)
• CAS NO: 13726-21-1
• Molecular Formula: C₉H₈ClNO
• Molecular Weight: 181.62
• Mol File: 13726-21-1.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: (4-CHLORO-3-METHOXYPHENYL)ACETONITRILE(CAS DataBase Reference)
• NIST Chemistry Reference: (4-CHLORO-3-METHOXYPHENYL)ACETONITRILE(13726-21-1)
• EPA Substance Registry System: (4-CHLORO-3-METHOXYPHENYL)ACETONITRILE(13726-21-1)

Safety Data

• Hazardous Substances Data: 13726-21-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(4-CHLORO-3-METHOXYPHENYL)ACETONITRILE is used as an intermediate in the synthesis of active pharmaceutical ingredients. Its unique chemical structure allows it to be a key component in the development of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
(4-CHLORO-3-METHOXYPHENYL)ACETONITRILE is also used in the synthesis of agrochemicals, contributing to the development of new pesticides and other agricultural chemicals that can improve crop protection and yield.
Used in Organic Synthesis:
As a building block in organic synthesis, (4-CHLORO-3-METHOXYPHENYL)ACETONITRILE can be utilized in the creation of various organic compounds for research and industrial applications.
Safety Measures:
Due to its potential hazardous nature, it is crucial to handle and store (4-CHLORO-3-METHOXYPHENYL)ACETONITRILE with proper safety measures in place to ensure the safety of personnel and the environment.

Upstream product

• 143-33-9 sodium cyanide 
• 13726-18-6 1-chloro-4-chloromethyl-2-methoxybenzene 
• 97-52-9 2-methoxy-4-nitrophenylamine 
• 7677-24-9 trimethylsilyl cyanide 
• 85740-98-3 4-chloro-3-methoxybenzoic acid 
• 615-74-7 2-chloro-5-methylphenol 
• 103347-14-4 4-(bromomethyl)-1-chloro-2-methoxybenzene 
• 73909-16-7 2-chloro-5-methylanisole 
• 773837-37-9 sodium cyanide 
• 13726-14-2 4-chloro-m-anisidine 
• 1009-36-5 2-chloro-5-nitroanisole 
• 13726-17-5 (4-chloro-3-methoxyphenyl)methan-1-ol 
• 13726-16-4 4-chloro-3-methoxybenzaldehyde 
• 151-50-8 potassium cyanide 

Downstream Products

• 1184103-48-7 2-(4-chloro-3-methoxyphenyl)-3-oxo-3-pyridin-4-ylpropanenitrile 
• 850564-15-7 2-(4-Chloro-3-methoxy-phenyl)-2-methyl-propionitrile 
• 936727-47-8 2-(3-(benzyloxy)-4-chlorophenyl)acetonitrile 
• 672931-86-1 (4-Chloro-3-hydroxyphenyl) acetic acid methyl ester 
• 1184103-08-9 12-benzyl-3-(4-chloro-3-methoxyphenyl)-8-(phenylsulfonyl)-2-pyridin-4-yl-7,8,9,10-tetrahydro-6H-7,10-epiminocyclohepta[e]pyrazolo[1,5-a]pyrimidine 
• 1184103-00-1 2-chloro-5-[12-methyl-8-(phenylsulfonyl)-2-pyridin-4-yl-7,8,9,10-tetrahydro-61-1-7,10-epiminocyclo-hepta[e]pyrazolo[1,5-a]pyrimidin-3-yl]phenol 
• 1184103-03-4 methyl 3-(4-chloro-3-hydroxyphenyl)-12-methyl-2-pyridin-4-yl-7,8,9,10-tetrahydro-6H-7,10-epiminocyclohepta-[e]pyrazolo[1,5-a]pyrimidine-8-carboxylate 
• 1184103-06-7 2-chloro-5-[8-(hydroxymethyl)-12-methyl-2-pyridin-4-yl-7,8,9,10-tetrahydro-6H-7,10-epiminocyclo-hepta[e]pyrazolo[1,5-a]pyrimidin-3-yl]phenol 
• 1184103-49-8 3-chloro-2-(4-chloro-3-methoxyphenyl)-3-pyridin-4-ylacrylonitrile 
• 1134598-81-4 5-(3-amino-5-pyridin-4-yl-1H-pyrazol-4-yl)-2-chlorophenol 
• 1134598-79-0 4-(4-chloro-3-methoxyphenyl)-5-pyridin-4-yl-1H-pyrazol-3-amine 
• 936727-34-3 (4-chloro-3-hydroxy-phenyl)acetonitrile 
• 867366-60-7 ethyl 4-chloro-3-methoxyphenylmethylimidate hydrochloride 
• 13726-25-5 3-Methoxy-4-chlor-phenylacetylhomoveratrylamin 

Relevant articles and documents

HETEROCYCLIC COMPOUND, APPLICATION THEREOF, AND COMPOSITION CONTAINING SAME

A heterocyclic compound represented by formula XI, a pharmaceutically acceptable salt, a solvate, or a solvate of a pharmaceutically acceptable salt thereof, use thereof, and a composition containing the same. The compound is novel in structure and has good STAT5 inhibitory activity.

PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (A), and sub-formulas thereof, or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatmen

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

TGR5 AGONISTS

TGR5 agonists of structural formula VIII(Q), wherein X, R1, R2, and R5 are defined in the specification, pharmaceutically acceptable salts thereof, compositions thereof, and use of the compounds and compositions for treating diseases. The invention also comprises use of the compounds in and for the manufacture of medicaments, particularly for treating diseases.

TRIAZOLE AND IMIDAZOLE DERIVATIVES FOR USE AS TGR5 AGONISTS IN THE TREATMENT OF DIABETES AND OBESITY

The present invention comprises TGR5 agonists of structural formula I, wherein X, R1, R2, and R5 are defined herein, as well as N-oxides of them and pharmaceutically acceptable salts thereof. The invention further comprise

ARYLACETATE DERIVATIVE HAVING ISOXAZOLE SKELETON

A compound of the formula (I): pharmaceutically acceptable salt or solvate thereof, wherein Y is a group of the formula: wherein Ring A is optionally substituted aryl or optionally substituted heteroaryl, X3 is COOR17 or the like Y i

Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease

The invention relates to substituted diphenylethers, -amines, -sulfides, and -methanes as useful pharmaceutical compounds for treating respiratory-disorders, pharmaceutical compositions containing them, and processes for their preparation.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

NOVEL COMPOUNDS

The invention relates to substituted phenylacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.